

Telisotuzumab

Cat. No.:	HY-P99391
CAS No.:	1781223-80-0
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Telisotuzumab (ABT-700) is a human recombinant bivalent antibody, a therapeutic antibody against the hepatocyte growth factor receptor (MET) that binds c-Met with high affinity and inhibits c-Met signaling. Telisotuzumab has antitumor activity ^[1] .	
In Vitro	Telisotuzumab (ABT-700) (10 µg/mL, 24 h) inhibits the proliferation of SNU5 cells and leads to an increase in pro-apoptotic Bim and a decrease in anti-apoptotic Bcl-xL, thereby inducing apoptosis ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	Telisotuzumab (ABT-700) (i.p., 2.5-40 mg/kg, twice a week, 90 days) effectively antagonizes constitutively activated c-Met and downstream signaling, thereby inhibiting tumor growth in SCID mice with Hs746T cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	SCID mice with Hs746T cells ^[1]
	Dosage:	2.5-40 mg/kg
	Administration:	i.p., twice a week, 90 days
	Result:	Reduced total and phosphorylated c-Met as well as phosphorylated Akt and Erk. Complete tumor regression at doses above 10 mg/kg but no effective inhibition of tumor growth at doses below 5mg/kg.

REFERENCES

[1]. Jieyi Wang, et al. Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification. BMC Cancer. 2016 Feb 16;16:105.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA